Quick Answer
ImmunityBio, Inc. reported Diluted EPS of $0.38 per share (loss) for fiscal year 2025.
ImmunityBio, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.38 | +38.7% |
| 2024 | -$0.62 | +46.1% |
| 2023 | -$1.15 | -10.6% |
| 2022 | -$1.04 | -16.9% |
| 2021 | -$0.89 | -50.8% |
| 2020 | -$0.59 | -37.2% |
| 2019 | -$0.43 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.07 | +50.0% | +30.0% |
| June 30, 2025 | -$0.10 | +50.0% | +33.3% |
| March 31, 2025 | -$0.15 | +25.0% | -7.1% |
| September 30, 2024 | -$0.14 | +26.3% | +30.0% |
| June 30, 2024 | -$0.20 | +37.5% | +0.0% |
| March 31, 2024 | -$0.20 | +25.9% | -5.3% |
| September 30, 2023 | -$0.19 | +32.1% | +40.6% |
| June 30, 2023 | -$0.32 | -33.3% | -18.5% |
- ImmunityBio, Inc. showed an increase of +38.7% in Diluted EPS compared to the prior fiscal year.
- Over the 2019–2025 period, ImmunityBio, Inc.’s diluted eps has grown by 11.6% (from $0.43 per share (loss) to $0.38 per share (loss)).
- The most recent figure is from ImmunityBio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: